TransCode Therapeutics, Inc. (RNAZ), a company focused on cancer treatment using RNA therapeutics, said on Monday that its Board has approved a 1-for-33 reverse stock split.
This move aims to increase the per share trading price to enable the firm to satisfy the minimum bid price requirement for continued listing on the Nasdaq.
The 1-for-33 reverse stock split will automatically convert 33 current RNAZ shares into one new share.
The reverse split will reduce the number of shares from 17,265,658 shares to around 523,202 shares, the company said.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.